Extrait

The primary objective of this study is to further assess the safety of dasatinib when administered 100 mg QD in CP CML subjects or 140 mg QD in AD CML or Ph+ ALL subjects as measured by the incidence and severity of adverse events, dose interruptions, dose reductions and treatment discontinuation due to drug-related adverse events.

Critère d'inclusion

• Subjects with Chronic or Advanced Phase Chronic Myelogenous Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) who are Resistant or Intolerant to Imatinib

Liens

• ictrp
• ictrp
• euctr
• ictrp
• euctr